The U.S. FDA said that BD (NYSE:BDX) has expanded its Class I voluntary recall to inform customers about the worst-case performance of the BD Alaris Pump Module model 8100 when used with certain ...
BD will pay a $175 million civil penalty to settle charges from the Securities and Exchange Commission that the company misled investors about problems with its Alaris infusion pumps. The SEC issued a ...
BD has expanded a Class I Alaris recall to cover 15 additional pump infusion sets, the company said Friday. The Food and Drug Administration posted the company's notice on Monday. The company added ...
FRANKLIN LAKES, N.J., July 18, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today provided an update on two voluntary recalls ...
To data, there have been 13 reported injuries. Becton Dickinson (BD)/Carefusion 303 is recalling the Alaris infusion pump due to incompatibility issues with Cardinal Health Monoject syringes. The Food ...